TTY Biopharm Co Ltd Cash Flow-to-Debt Ratio
TTY Biopharm Co Ltd cash flow-to-debt ratio. TTY Biopharm Co Ltd (4105) has a Cash Flow-to-Debt Ratio of 0.15x as of March 2026, meaning its operating cash flow of NT$654.16 Million could theoretically repay 0% of its total liabilities (NT$4.28 Billion) in one year. Check 4105 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of TTY Biopharm Co Ltd (2017–2025)
Cash flow-to-debt ratio of TTY Biopharm Co Ltd from 2017 to 2025. Historical debt coverage capacity for TTY Biopharm Co Ltd across 9 annual periods. Check TTY Biopharm Co Ltd (4105) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
TTY Biopharm Co Ltd Cash Flow-to-Debt Ratio by Year (2017–2025)
TTY Biopharm Co Ltd cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for TTY Biopharm Co Ltd. For the full cash flow conversion analysis, see TTY Biopharm Co Ltd cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.53x | NT$1.76 Billion | NT$3.30 Billion | ▲ +32.7% |
| 2024 | 0.40x | NT$1.35 Billion | NT$3.35 Billion | ▲ +25.0% |
| 2023 | 0.32x | NT$1.09 Billion | NT$3.37 Billion | ▼ -12.2% |
| 2022 | 0.37x | NT$1.24 Billion | NT$3.37 Billion | ▲ +3.1% |
| 2021 | 0.36x | NT$1.26 Billion | NT$3.53 Billion | ▲ +122.0% |
| 2020 | 0.16x | NT$526.35 Million | NT$3.28 Billion | ▼ -55.2% |
| 2019 | 0.36x | NT$1.21 Billion | NT$3.38 Billion | ▼ -11.4% |
| 2018 | 0.40x | NT$1.07 Billion | NT$2.66 Billion | ▲ +37.5% |
| 2017 | 0.29x | NT$996.52 Million | NT$3.40 Billion | — |